raloxifene hydrochloride has been researched along with Carcinoma in Situ in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bevers, TB | 1 |
| Burdette, JE; Davis, DA; Dean, M; Moyle-Heyrman, G; Schipma, MJ | 1 |
| Hoshi, SL; Kondo, M; Toi, M | 1 |
| Cutuli, B; Kerbrat, P; Lesur, A; Namer, M | 1 |
| Costantino, JP; Cronin, WM; Vogel, VG; Wickerham, DL | 1 |
| Dunn, BK; Wolmark, N | 1 |
2 review(s) available for raloxifene hydrochloride and Carcinoma in Situ
| Article | Year |
|---|---|
[Breast cancer chemoprevention. Rational, trials results and future].
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Family Health; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2009 |
National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Humans; Mastectomy; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen | 2003 |
1 trial(s) available for raloxifene hydrochloride and Carcinoma in Situ
| Article | Year |
|---|---|
The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1).
Topics: Breast Neoplasms; Carcinoma in Situ; Drug Resistance; Estrogen Receptor Modulators; Female; Humans; Raloxifene Hydrochloride; Tamoxifen; United States | 2001 |
4 other study(ies) available for raloxifene hydrochloride and Carcinoma in Situ
| Article | Year |
|---|---|
Breast cancer risk reduction therapy: the low-hanging fruit.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma in Situ; Female; Humans; Hyperplasia; Nitriles; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2015 |
Genome-wide transcriptional regulation of estrogen receptor targets in fallopian tube cells and the role of selective estrogen receptor modulators.
Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma in Situ; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogens; Fallopian Tubes; Female; Gene Expression Regulation, Neoplastic; Genome; Humans; Mice; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Thiophenes; Transcriptome | 2016 |
Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Lobular; Cost-Benefit Analysis; Female; Humans; Japan; Markov Chains; Middle Aged; Neoplasm Invasiveness; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Tamoxifen | 2009 |
Designer estrogens: breast cancer benefit, remaining questions.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Estrogen Antagonists; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1999 |